Clinical Trial Search

Primary: Percentage of Participants With Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/Milliliter (c/mL) Regardless of Antiretroviral…

Primary: Change in HbA1c From Baseline at Week 24 — -0.51; -0.10 % of HbA1c — p=0.0012

Primary: Change From Baseline in HbA1c at 24 Weeks — -0.59; -0.31 percentage of glycated hemoglobin — p=0.0026

Primary: Stage I: Percentage of Participants With Seroresponse for Meningococcal Serogroups A, C, W & Y Measured by Serum Bactericidal Assay Using Human Complement (hSBA) After…

Primary: Cumulative Incidence of Recovery of Level of Consciousness Defined as a Glasgow Coma Scale (GCS) GCS ≥ 13 [Time Frame: 90 Minutes Post-randomization] — 4; 2 Participants

Primary: Subjects With Change From Baseline in Serum Bicarbonate of ≥ 4 mEq/L or Serum Bicarbonate Within the Normal Range — 59.2; 22.5; 55.8; 21.3 percentage of participants…

Primary: Overall Occurrence of Treatment Emergent Adverse Events (TEAEs) — 270 Participants

Primary: Time to Recovery — 7.0; 8.0 Days — p=0.047

Primary: Progression-Free Survival (PFS) — 27.6; 4.1 Weeks — p=<0.0001

Primary: Homogentisic Acid Excretion — 1425.9; 113.1; 34.0 uM

Primary: Systemic Inflammatory Response Syndrome (SIRS) Score — -0.96; -1 score on a scale — p=0.87

Primary: Induction Study: Percentage of Participants Who Achieved Endoscopy/Bleeding/Stool Frequency (EBS) Remission at Week 10 — 26.1; 19.1; 15.3; 11.5 percentage of…

Primary: Measure the Number of Patients Who Had an Increase of ≥20 Points on the Total Improvement Score (TIS) — 21; 37 Participants

Primary: Duration of Hypoxemia — 0.7; 1.1 min/h — p=0.29

Primary: Mean Change in the Total WOMAC Pain Subscale Score — -4.3; -4.6 score on a scale